Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
A. Zanghì & E. D’Amico. (2019) New treatment targets in multiple sclerosis therapy. Expert Review of Precision Medicine and Drug Development 4:4, pages 201-203.
Read now
Read now
Articles from other publishers (26)
Aigli G Vakrakou, Maria-Evgenia Brinia, Anastasia Alexaki, Evangelos Koumasopoulos, Panos Stathopoulos, Maria-Eleftheria Evangelopoulos, Leonidas Stefanis, Christine Stadelmann-Nessler & Constantinos Kilidireas. (2023) Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice. International Immunopharmacology 125, pages 111192.
Crossref
Crossref
Nik Krajnc, Gabriel Bsteh, Thomas Berger, Jan Mares & Hans-Peter Hartung. (2022) Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics 19:3, pages 753-773.
Crossref
Crossref
Hannah Kelly, Brent Sokola & Hesham Abboud. (2021) Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. Journal of Neuroimmunology 356, pages 577599.
Crossref
Crossref
Ilaria Callegari, Tobias Derfuss & Edoardo Galli. (2021) Update on treatment in multiple sclerosis. La Presse Médicale 50:2, pages 104068.
Crossref
Crossref
Aurora Zanghì, Antonio Gallo, Carlo Avolio, Rocco Capuano, Matteo Lucchini, Maria Petracca, Simona Bonavita, Roberta Lanzillo, Diana Ferraro, Erica Curti, Maria Buccafusca, Graziella Callari, Stefania Barone, Giuseppe Pontillo, Gianmarco Abbadessa, Valeria Di Francescantonio, Elisabetta Signoriello, Giacomo Lus, Patrizia Sola, Franco Granella, Paola Valentino, Massimiliano Mirabella, Francesco Patti & Emanuele D’Amico. (2021) Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics 18:2, pages 1166-1174.
Crossref
Crossref
Neda Razaz, Fredrik PiehlThomas FrisellAnnette M. Langer-GouldKyla A. McKayKatharina Fink. (2020) Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurology Neuroimmunology & Neuroinflammation 7:6.
Crossref
Crossref
Tobias Moser, Katja Akgün, Undine Proschmann, Johann Sellner & Tjalf Ziemssen. (2020) The role of TH17 cells in multiple sclerosis: Therapeutic implications. Autoimmunity Reviews 19:10, pages 102647.
Crossref
Crossref
Filipa Ladeira, Luís Braz, Paula Salgado, Soraia Vaz, Lia Leitão, Catarina Félix, Ana Sofia Correia, Ana Martins da Silva, Vasco Salgado, Fátima Ferreira, José Vale, Maria José de Sá & Carlos Capela. (2019) A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal. Clinical Neurology and Neurosurgery 184, pages 105390.
Crossref
Crossref
Paulus S. Rommer, Ron Milo, May H. Han, Sammita Satyanarayan, Johann Sellner, Larissa Hauer, Zsolt Illes, Clemens Warnke, Sarah Laurent, Martin S. Weber, Yinan Zhang & Olaf Stuve. (2019) Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology 10.
Crossref
Crossref
A. Mariottini, C. Innocenti, B. Forci, E. Magnani, C. Mechi, A. Barilaro, R. Nistri, A. Fani, R. Saccardi, L. Massacesi & A. M. Repice. (2018) Safety and efficacy of autologous hematopoietic stem‐cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis. European Journal of Neurology 26:4, pages 624-630.
Crossref
Crossref
Florian Deisenhammer, Marlies Jank, Anna Lauren, Anders Sjödin, Malin Ryner, Anna Fogdell-Hahn, Claudia Sievers, Raija Lindberg, Poul Erik Jensen, Finn Sellebjerg, Louis Christodoulou, Mary Birchler, Marc Pallardy, Michael Auer & Roland Liblau. (2018) Prediction of natalizumab anti-drug antibodies persistency. Multiple Sclerosis Journal 25:3, pages 392-398.
Crossref
Crossref
Daniel R. Wynn. (2019) Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. Multiple Sclerosis International 2019, pages 1-19.
Crossref
Crossref
Anjiao Peng, Xiangmiao Qiu, Lin Zhang, Xi Zhu, Shixu He, Wanlin Lai & Lei Chen. (2019) Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. Journal of the Neurological Sciences 396, pages 202-205.
Crossref
Crossref
Shiori Asano, Hideyuki Takeuchi, Keisuke Morihara, Keita Takahashi, Kenichi Tanaka, Yuichi Higashiyama, Hiroshi Doi, Shigeru Koyano & Fumiaki Tanaka. (2018) Severe rebound relapse of multiple sclerosis after switching from fingolimod to dimethyl fumarate. Clinical and Experimental Neuroimmunology 9:3, pages 173-176.
Crossref
Crossref
Ilya Kister, Tim Spelman, Francesco Patti, Pierre Duquette, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Pierre Grammond, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Raed Alroughani, Murat Terzi, Cavit Boz, Raymond Hupperts, Jeannette Lechner-Scott, Ludwig Kappos, Eugenio Pucci, Suzanne Hodgkinson, Claudio Solaro & Helmut Butzkueven. (2018) Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences 391, pages 72-76.
Crossref
Crossref
Barbara Scotti, Giulio Disanto, Rosaria Sacco, Marilu’ Guigli, Chiara Zecca & Claudio Gobbi. (2018) Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLOS ONE 13:5, pages e0197415.
Crossref
Crossref
Gitanjali DasVincent DamotteJeffrey M. GelfandCarolyn BevanBruce A.C. CreeLynn DoAri J. GreenStephen L. HauserRiley Bove. (2018) Rituximab before and during pregnancy. Neurology Neuroimmunology & Neuroinflammation 5:3.
Crossref
Crossref
C. Zecca, S. Roth, O. Findling, G. Perriard, V. Bachmann, M. L. Pless, A. Baumann, C. P. Kamm, P. H. Lalive & A. Czaplinski. (2018) Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis. European Journal of Neurology 25:5, pages 762-767.
Crossref
Crossref
Chiara Zecca, Arianna Merlini, Giulio Disanto, Mariaemma Rodegher, Letizia Panicari, Marzia Anita Lucia Romeo, Ursula Candrian, Maria Josè Messina, Emanuele Pravatà, Lucia Moiola, Catia Stefanin, Angelo Ghezzi, Patrizia Perrone, Francesco Patti, Giancarlo Comi, Claudio Gobbi & Vittorio Martinelli. (2017) Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Multiple Sclerosis Journal 24:2, pages 167-174.
Crossref
Crossref
Timo Uphaus, Christoph Oberwittler, Sergiu Groppa, Frauke Zipp & Stefan Bittner. (2017) Disease reactivation after switching from natalizumab to daclizumab. Journal of Neurology 264:12, pages 2491-2494.
Crossref
Crossref
Alasdair J. ColesJeffrey A. CohenEdward J. FoxGavin GiovannoniHans-Peter HartungEva HavrdovaSven SchipplingKrzysztof W. SelmajAnthony TraboulseeD. Alastair S. CompstonDavid H. MargolinKarthinathan ThangaveluMadalina C. ChirieacDarlene JodyPanos XenopoulosRichard J. HoganMichael A. PanzaraDouglas L. Arnold. (2017) Alemtuzumab CARE-MS II 5-year follow-up. Neurology 89:11, pages 1117-1126.
Crossref
Crossref
Tobias DerfussJohn M. KovarikLudwig KapposMarina SavelievaRicha ChhabraAvinash ThakurYing ZhangHeinz WiendlDavorka Tomic. (2017) α4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurology Neuroimmunology & Neuroinflammation 4:5.
Crossref
Crossref
Barbara Serafini, Eleonora Scorsi, Barbara Rosicarelli, Valérie Rigau, Eric Thouvenot & Francesca Aloisi. (2017) Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal. Journal of Neuroimmunology 307, pages 14-17.
Crossref
Crossref
David Baker, Monica Marta, Gareth Pryce, Gavin Giovannoni & Klaus Schmierer. (2017) Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine 16, pages 41-50.
Crossref
Crossref
Trygve Holmøy, Antonie G. Beiske, Svetozar Zarnovicky, Aija Zuleron Myro, Egil Røsjø & Emilia Kerty. (2016) Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber’s optic neuropathy and multiple sclerosis – a case report. BMC Neurology 16:1.
Crossref
Crossref
Trygve Holm?y & ?ivind Torkildsen. (2016) Familieplanlegging, graviditet og amming ved multippel sklerose. Tidsskrift for Den norske legeforening 136:20, pages 1726-1729.
Crossref
Crossref